by Team Small News | Apr 15, 2025 | Biocon, Pharma
Biocon Biologics, a biopharmaceutical company, has reached a settlement and license agreement with Regeneron to commercialize its aflibercept-jbvf (Yesafili) biosimilar, an interchangeable version of Regeneron’s aflibercept, in the United States. The agreement... by Team Small News | Apr 12, 2025 | Biocon, Pharma
Siddharth Mittal, CEO of Biocon Limited, has questioned the feasibility of shifting pharmaceutical manufacturing back to the US due to higher costs. At the Carnegie Global Technology Summit, he pointed out that Indian companies cannot afford to bring back... by Team Small News | Apr 11, 2025 | Biocon, Pharma
Siddharth Mittal, CEO and Managing Director of Biocon Limited, expressed concerns about the feasibility of shifting pharmaceutical manufacturing from India and China to the US, due to the significant cost difference. He stated that if a drug is manufactured in China,... by Team Small News | Mar 27, 2025 | Biocon, Pharma
Kiran Mazumdar Shaw, the founder of Biocon, recently expressed her disappointment with Bengaluru’s civic infrastructure on social media. She shared a picture of clean streets in San Cristobal Island, Ecuador, and compared it unfavorably to Bengaluru, stating,... by Team Small News | Mar 24, 2025 | Biocon, Pharma
Biocon’s arm, Biocon Pharma, has received approval for its Norepinephrine Bitartrate Injection in the US, expanding its portfolio of complex injectables. The injection will be used to treat adults with acute hypotension and sodium nitroprusside/control of blood... by Team Small News | Mar 22, 2025 | Biocon, Cipla, Lupin, Mankind, Natco, Pharma
Eli Lilly & Co. has launched its anti-obesity drug Mounjaro in India, making it the country’s first treatment of its kind. The drug, which is used to treat obesity and type-2 diabetes, works by activating hormones that help reduce the amount of sugar in the...